Amifostine Injection

Description:
Amifostine Injection is a specialized pharmaceutical product presented as a sterile dry powder for reconstitution, with a strength of 100 mg per vial. This innovative formulation is designed to provide a protective effect against certain side effects associated with certain cancer treatments. Amifostine is recognized for its cytoprotective properties, making it a valuable addition to oncology protocols to enhance the well-being of patients undergoing radiation or chemotherapy.

Indication:
Amifostine Injection is indicated for use as a cytoprotective agent to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. It may also be employed to reduce xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer.

Dosage and Administration:
The dosage of Amifostine is determined by the treating physician based on the patient’s specific medical condition, type of cancer treatment, and other relevant factors. The dry powder is reconstituted with a suitable diluent and administered intravenously under the supervision of trained healthcare professionals.

Packaging:
Amifostine Injection is conveniently packaged in vials containing a sterile dry powder. This presentation ensures the stability and potency of the product, allowing for easy reconstitution before administration. The vials are designed to maintain the sterility and integrity of the product, providing healthcare professionals with confidence in its efficacy.

Disclaimer:
This product information is intended for healthcare professionals and should not be used as a substitute for professional medical advice. Patients are advised to consult their healthcare providers for personalized guidance on the use of Amifostine Injection. This information may be subject to updates, and users are encouraged to verify the latest details from the pharmaceutical company or healthcare provider.